Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE.

Dominique Prétot,Ivette Engel-Bicik,David Kenkel,Philipp A Kaufmann,Valerie Treyer,Alexander R Siebenhüner

Journal of gastrointestinal oncology（2023）

引用 0|浏览1

暂无评分

摘要

Patients with advanced GEP-NET might benefit from PRRT with Lu-177-DOTATATE as it can provide a valuable treatment modality in advanced disease stages. Safety profiles of PRRT were manageable without increasing the symptomatic burden. SIRT before PRRT or lack of SSA after PRRT seem to impair the response and reduce survival.

查看译文

关键词

metastatic gastroenteropancreatic neuroendocrine tumors,peptide receptor radionuclide therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要